Accéder au contenu
Merck

A Combination of CRISPR/Cas9 and Standardized RNAi as a Versatile Platform for the Characterization of Gene Function.

G3 (Bethesda, Md.) (2016-06-10)
Sebastian Wissel, Anja Kieser, Tetsuo Yasugi, Peter Duchek, Elisabeth Roitinger, Joseph Gokcezade, Victoria Steinmann, Ulrike Gaul, Karl Mechtler, Klaus Förstemann, Jürgen A Knoblich, Ralph A Neumüller
RÉSUMÉ

Traditional loss-of-function studies in Drosophila suffer from a number of shortcomings, including off-target effects in the case of RNA interference (RNAi) or the stochastic nature of mosaic clonal analysis. Here, we describe minimal in vivo GFP interference (miGFPi) as a versatile strategy to characterize gene function and to conduct highly stringent, cell type-specific loss-of-function experiments in Drosophila miGFPi combines CRISPR/Cas9-mediated tagging of genes at their endogenous locus with an immunotag and an exogenous 21 nucleotide RNAi effector sequence with the use of a single reagent, highly validated RNAi line targeting this sequence. We demonstrate the utility and time effectiveness of this method by characterizing the function of the Polymerase I (Pol I)-associated transcription factor Tif-1a, and the previously uncharacterized gene MESR4, in the Drosophila female germline stem cell lineage. In addition, we show that miGFPi serves as a powerful technique to functionally characterize individual isoforms of a gene. We exemplify this aspect of miGFPi by studying isoform-specific loss-of-function phenotypes of the longitudinals lacking (lola) gene in neural stem cells. Altogether, the miGFPi strategy constitutes a generalized loss-of-function approach that is amenable to the study of the function of all genes in the genome in a stringent and highly time effective manner.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-V5 antibody, Mouse monoclonal, clone V5-10, purified from hybridoma cell culture